Sign in

Private company

PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A. is a biological products company.1

Last updated Oct 21, 2026.

Overview

0Revenue, fiscal 20222
-228.0KNet income, fiscal 20222
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersI01
  • Incorporated inFrance3
  • Business address60 Avenue Rockefeller, Batiment Adenine, Lyon, I0 690083
  • Filer categoryNon-accelerated filer3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2022

-1.0%Return on equity2
0.32×Debt to equity2
-31.8M EURFree cash flow2

Financial statements

Revenue45620 EUR in 2022
02015: 0 EUR0 EUR20152016: 0 EUR0 EUR20162017: 0 EUR0 EUR20172018: 0 EUR0 EUR20182019: 0 EUR0 EUR20192020: 0 EUR0 EUR20202021: 0 EUR0 EUR20212022: 0 EUR0 EUR2022
Operating income478562-2.8M EUR in 2022−82% since 2015
-80.0M EUR-60.0M EUR-40.0M EUR-20.0M EUR02015: -15.6M EUR-15.6M EUR20152016: -22.4M EUR-22.4M EUR2016+44%2017: -30.9M EUR-30.9M EUR2017+38%2018: -43.6M EUR-43.6M EUR2018+41%2019: -64.1M EUR-64.1M EUR2019+47%2020: -68.8M EUR-68.8M EUR2020+7%2021: -56.5M EUR-56.5M EUR2021−18%2022: -2.8M EUR-2.8M EUR2022−95%
Net income478562-228.0K EUR in 2022−98% since 2015
-80.0M EUR-60.0M EUR-40.0M EUR-20.0M EUR02015: -15.0M EUR-15.0M EUR20152016: -21.9M EUR-21.9M EUR2016+46%2017: -33.5M EUR-33.5M EUR2017+53%2018: -38.2M EUR-38.2M EUR2018+14%2019: -62.7M EUR-62.7M EUR2019+64%2020: -73.3M EUR-73.3M EUR2020+17%2021: -53.8M EUR-53.8M EUR2021−27%2022: -228.0K EUR-228.0K EUR2022−100%
Fiscal year20152016201720182019202020212022
Revenue0 EUR40 EUR40 EUR40 EUR50 EUR60 EUR20 EUR20 EUR2
Research and development45.1M EUR219.9M EUR2
Operating income-15.6M EUR4-22.4M EUR7-30.9M EUR8-43.6M EUR5-64.1M EUR6-68.8M EUR2-56.5M EUR2-2.8M EUR2
Interest2.7M EUR21.4M EUR2
Income before tax-53.8M EUR2293.0K EUR2
Net income-15.0M EUR4-21.9M EUR7-33.5M EUR8-38.2M EUR5-62.7M EUR6-73.3M EUR2-53.8M EUR2-228.0K EUR2
Earnings per share-2 EUR/shares4-3 EUR/shares7-3 EUR/shares8-2 EUR/shares5-3 EUR/shares6-4 EUR/shares2-2 EUR/shares2-0 EUR/shares2
Earnings per share (diluted)-2 EUR/shares4-3 EUR/shares7-3 EUR/shares8-2 EUR/shares5-3 EUR/shares6-4 EUR/shares2-2 EUR/shares2-0 EUR/shares2
Shares (weighted, basic)23.7M shares231.0M shares2

Compare PHAXIAM Therapeutics S.A. with another company

Corporate structure

PHAXIAM Therapeutics S.A. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of PHAXIAM Therapeutics S.A.

  • PHAXIAM Therapeutics S.A. I0

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What PHAXIAM Therapeutics S.A. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net393.0K EUR2 Dec 31, 202219.0M EUR2 Dec 31, 2021−97.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents38.8M EUR2 Dec 31, 202233.7M EUR2 Dec 31, 2021+15.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)5.0K EUR2 Dec 31, 202215.0K EUR2 Dec 31, 2021−66.7%

Inventory

ItemLatestA year beforeChange
Inventory, total0 EUR2 Dec 31, 20220 EUR2 Dec 31, 2021

Former names

  • Erytech Pharma S.A.Aug 21, 2015 to Jun 28, 20233
  • Erytech PharmaNov 7, 2014 to Oct 23, 20153

Filings

65 filings to the SEC since October 2021: 2 annual reports, 5 large holders, 58 other. The latest 20:

  1. Mar 11, 202415F-12B EDGAR
  2. Mar 5, 2024EFFECT EDGAR
  3. Mar 4, 2024S-8 POS EDGAR
  4. Mar 4, 2024S-8 POS EDGAR
  5. Mar 4, 2024S-8 POS EDGAR
  6. Mar 4, 2024S-8 POS EDGAR
  7. Mar 4, 2024S-8 POS EDGAR
  8. Mar 4, 2024POS AM EDGAR
  9. Mar 1, 202425 EDGAR
  10. Feb 21, 20246-K EDGAR
  11. Jan 19, 20246-K EDGAR
  12. Nov 16, 20236-K EDGAR
  13. Oct 25, 20236-K EDGAR
  14. Oct 11, 20236-K EDGAR
  15. Oct 5, 20236-K EDGAR
  16. Sep 26, 20236-K EDGAR
  17. Sep 21, 20236-K EDGAR
  18. Sep 18, 20236-K EDGAR
  19. Sep 15, 20236-K EDGAR
  20. Sep 7, 20236-K EDGAR

The 65 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How PHAXIAM Therapeutics S.A. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPHAXIAM Therapeutics S.A.1
  • CIK0001624422
  • Filer statusNon-accelerated filer1
  • Incorporated inFrance1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address60 Avenue Rockefeller, Batiment Adenine, Lyon, I0 690081
  • Phone011-33-4-78-74-44-381
  • Shares outstanding31,018,553 as of Dec 31, 20222
  • On EDGAR sinceNov 7, 20141
  • Filings189 in all: 6-K (94), UPLOAD (8), CORRESP (7), 20-F (6), EFFECT (6), SC 13D/A (6), S-8 (5), S-8 POS (5)1
    All 36 form types

    SC 13G/A (5), 424B5 (4), DRS/A (4), DRSLTR (3), F-3 (3), SC 13G (3), 424B3 (2), CT ORDER (2), D (2), F-1/A (2), F-3/A (2), F-6 POS (2), FWP (2), SC 13D (2), 15F-12B (1), 20-F/A (1), 25 (1), 424B4 (1), 6-K/A (1), 8-A12B (1), CB (1), CERTNAS (1), D/A (1), DRS (1), F-1 (1), F-6 (1), F-X (1), POS AM (1)

  • Latest filingsAnnual report (20-F) Mar 28, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10